Clinical Trial Update: Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating ASP0739 alone and in combination with pembrolizumab in NY-ESO-1 expressing advanced solid tumors was terminated, with results posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma
• Non-small Cell Lung Cancer
• Ovarian Cancer

Drugs mentioned

• ASP0739 (ASP0739)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: Ovarian Cancer, NSCLC | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-08-06